472 related articles for article (PubMed ID: 33491499)
1. A proteogenomic approach to target neoantigens in solid tumors.
Verma A; Halder A; Marathe S; Purwar R; Srivastava S
Expert Rev Proteomics; 2020; 17(11-12):797-812. PubMed ID: 33491499
[TBL] [Abstract][Full Text] [Related]
2. ProGeo-neo: a customized proteogenomic workflow for neoantigen prediction and selection.
Li Y; Wang G; Tan X; Ouyang J; Zhang M; Song X; Liu Q; Leng Q; Chen L; Xie L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):52. PubMed ID: 32241270
[TBL] [Abstract][Full Text] [Related]
3. Application of mass spectrometry-based MHC immunopeptidome profiling in neoantigen identification for tumor immunotherapy.
Zhang X; Qi Y; Zhang Q; Liu W
Biomed Pharmacother; 2019 Dec; 120():109542. PubMed ID: 31629254
[TBL] [Abstract][Full Text] [Related]
4. ProGeo-Neo v2.0: A One-Stop Software for Neoantigen Prediction and Filtering Based on the Proteogenomics Strategy.
Liu C; Zhang Y; Jian X; Tan X; Lu M; Ouyang J; Liu Z; Li Y; Xu L; Chen L; Lin Y; Xie L
Genes (Basel); 2022 Apr; 13(5):. PubMed ID: 35627168
[TBL] [Abstract][Full Text] [Related]
5. Proteogenomic discovery of neoantigens facilitates personalized multi-antigen targeted T cell immunotherapy for brain tumors.
Rivero-Hinojosa S; Grant M; Panigrahi A; Zhang H; Caisova V; Bollard CM; Rood BR
Nat Commun; 2021 Nov; 12(1):6689. PubMed ID: 34795224
[TBL] [Abstract][Full Text] [Related]
6. Proteogenomic Platform for Identification of Tumor Specific Antigens.
Faktor J; Hernychová L; Vojtěšek B; Hupp T
Klin Onkol; 2018; 31(Suppl 2):102-107. PubMed ID: 31023032
[TBL] [Abstract][Full Text] [Related]
7. Proteogenomic analysis identifies neoantigens and bacterial peptides as immunotherapy targets in colorectal cancer.
Yao P; Gao M; Hu W; Wang J; Wang Y; Wang Q; Ji J
Pharmacol Res; 2024 Jun; 204():107209. PubMed ID: 38740147
[TBL] [Abstract][Full Text] [Related]
8. [Identification of neoantigens and development of antigen-specific immunotherapy].
Shinohara S; Takahashi Y; Demachi-Okamura A; Matsushita H
Rinsho Ketsueki; 2020; 61(9):1433-1439. PubMed ID: 33162546
[TBL] [Abstract][Full Text] [Related]
9. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
[TBL] [Abstract][Full Text] [Related]
10. Neoantigen vaccine: an emerging tumor immunotherapy.
Peng M; Mo Y; Wang Y; Wu P; Zhang Y; Xiong F; Guo C; Wu X; Li Y; Li X; Li G; Xiong W; Zeng Z
Mol Cancer; 2019 Aug; 18(1):128. PubMed ID: 31443694
[TBL] [Abstract][Full Text] [Related]
11. PGNneo: A Proteogenomics-Based Neoantigen Prediction Pipeline in Noncoding Regions.
Tan X; Xu L; Jian X; Ouyang J; Hu B; Yang X; Wang T; Xie L
Cells; 2023 Mar; 12(5):. PubMed ID: 36899918
[TBL] [Abstract][Full Text] [Related]
12. Challenges targeting cancer neoantigens in 2021: a systematic literature review.
Chen I; Chen MY; Goedegebuure SP; Gillanders WE
Expert Rev Vaccines; 2021 Jul; 20(7):827-837. PubMed ID: 34047245
[No Abstract] [Full Text] [Related]
13. Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy?
Roerden M; Nelde A; Walz JS
Front Immunol; 2019; 10():3004. PubMed ID: 31921218
[TBL] [Abstract][Full Text] [Related]
14. Virus-like particle-mediated delivery of structure-selected neoantigens demonstrates immunogenicity and antitumoral activity in mice.
Barajas A; Amengual-Rigo P; Pons-Grífols A; Ortiz R; Gracia Carmona O; Urrea V; de la Iglesia N; Blanco-Heredia J; Anjos-Souza C; Varela I; Trinité B; Tarrés-Freixas F; Rovirosa C; Lepore R; Vázquez M; de Mattos-Arruda L; Valencia A; Clotet B; Aguilar-Gurrieri C; Guallar V; Carrillo J; Blanco J
J Transl Med; 2024 Jan; 22(1):14. PubMed ID: 38172991
[TBL] [Abstract][Full Text] [Related]
15. Neoantigen vaccine platforms in clinical development: understanding the future of personalized immunotherapy.
Supabphol S; Li L; Goedegebuure SP; Gillanders WE
Expert Opin Investig Drugs; 2021 May; 30(5):529-541. PubMed ID: 33641576
[TBL] [Abstract][Full Text] [Related]
16. Proteogenomics meets cancer immunology: mass spectrometric discovery and analysis of neoantigens.
Polyakova A; Kuznetsova K; Moshkovskii S
Expert Rev Proteomics; 2015; 12(5):533-41. PubMed ID: 26175083
[TBL] [Abstract][Full Text] [Related]
17. Engineering neoantigen vaccines to improve cancer personalized immunotherapy.
Liu Z; Lv J; Dang Q; Liu L; Weng S; Wang L; Zhou Z; Kong Y; Li H; Han Y; Han X
Int J Biol Sci; 2022; 18(15):5607-5623. PubMed ID: 36263174
[TBL] [Abstract][Full Text] [Related]
18. Tumor neoantigens: from basic research to clinical applications.
Jiang T; Shi T; Zhang H; Hu J; Song Y; Wei J; Ren S; Zhou C
J Hematol Oncol; 2019 Sep; 12(1):93. PubMed ID: 31492199
[TBL] [Abstract][Full Text] [Related]
19. Development of neoantigens: from identification in cancer cells to application in cancer vaccines.
Ebrahimi N; Akbari M; Ghanaatian M; Roozbahani Moghaddam P; Adelian S; Borjian Boroujeni M; Yazdani E; Ahmadi A; Hamblin MR
Expert Rev Vaccines; 2022 Jul; 21(7):941-955. PubMed ID: 34196590
[TBL] [Abstract][Full Text] [Related]
20. Best practices for bioinformatic characterization of neoantigens for clinical utility.
Richters MM; Xia H; Campbell KM; Gillanders WE; Griffith OL; Griffith M
Genome Med; 2019 Aug; 11(1):56. PubMed ID: 31462330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
